Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer
| Errataetall: |
CommentOn: Lancet. 2023 Dec 9;402(10418):2197-2208. - PMID 37871604 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:402 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 402(2023), 10418 vom: 09. Dez., Seite 2168-2170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smyth, Elizabeth C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comment |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 07.02.2024 published: Print-Electronic CommentOn: Lancet. 2023 Dec 9;402(10418):2197-2208. - PMID 37871604 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(23)02296-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363638938 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363638938 | ||
| 003 | DE-627 | ||
| 005 | 20240207232100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(23)02296-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM363638938 | ||
| 035 | |a (NLM)37871605 | ||
| 035 | |a (PII)S0140-6736(23)02296-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smyth, Elizabeth C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Lancet. 2023 Dec 9;402(10418):2197-2208. - PMID 37871604 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Sundar, Raghav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 402(2023), 10418 vom: 09. Dez., Seite 2168-2170 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:402 |g year:2023 |g number:10418 |g day:09 |g month:12 |g pages:2168-2170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(23)02296-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 402 |j 2023 |e 10418 |b 09 |c 12 |h 2168-2170 | ||